The Process of Angiogenesis & Inhibition of Angiogenesis and/or Lymphangiogenesis

Similar documents
The Angiopoietin Axis in Cancer

Nintedanib in Oncology Backgrounder

Angiogenesis as a therapeutic target

UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS

Inflammatory Cells and Metastasis

Angiogenesis in Human Development. Vascular Development

Tissue repair. (3&4 of 4)

Heterotypy and Angiogenesis

Mechanisms of Resistance to Antiangiogenic. Martin J. Edelman, MD University of Maryland Greenebaum Cancer Center Dresden, 2012

Review of relationship between vascular endothelial growth factor family & receptors and tumor angiogenesis

Backgrounder. 1. What are targeted therapies? 2. How do targeted therapies work?

Microenvironmental influence on angiogenesis and tumor cell survival. Mark W. Dewhirst, DVM, PhD Duke University Medical Center

Signaling Vascular Morphogenesis and Maintenance

!!! Oncology for Scientists (RPN 530) Metastasis and Angiogenesis Chapter 13 and 14 Oct. 28 th 2014

CD34 + VEGFR-3 + progenitor cells have a potential to differentiate towards lymphatic endothelial cells

Nexavar in advanced HCC: a paradigm shift in clinical practice

RIP-Tag2 mouse model as a Paradigm for Target. Search in NETs

Chronic exposure of VEGF inhibitors promotes the malignant phenotype of colorectal cancer cells

Tumor Associated Macrophages as a Novel Target for Cancer Therapy

1.The metastatic cascade. 2.Pathologic features of metastasis. 3.Therapeutic ramifications

Rationale for VEGFR-targeted Therapy in RCC

Predicting benefit from antiangiogenic

Colorectal Cancer Treatment Future Directions

HEM- AND LYMPH- ANGIOGENESIS IN CANCER METASTASIS

Mechanisms of Gene Regulation and Signal! Transduction in Hypoxia!

1. The metastatic cascade. 3. Pathologic features of metastasis. 4. Therapeutic ramifications. Which malignant cells will metastasize?

Colorectal Cancer Therapy and Associated Toxicity

Processing of VEGF-C and -D by the Proprotein Convertases: Importance in Angiogenesis, Lymphangiogenesis, and Tumorigenesis

Tissue renewal and Repair. Nisamanee Charoenchon, PhD Department of Pathobiology, Faculty of Science

Angiogenesis and tumor growth

PATHOBIOLOGY OF NEOPLASIA

Popperian Pathways: the demarcation between quack cancer cures and scientific remedies. Michael Baum UCL November 2007

Proc. Intl. Soc. Mag. Reson. Med. 22 (2014)

Oxygen-independent regulation of HIF-1α levels

Microvascular rarefaction, angiogenesis and hypertension

Angiogenesis in Ovarian Cancer

Curriculum Vitae Hui Yuan, MD

Tumor Microenvironment and Immune Suppression

Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF).

Biologics Effects of Targeted Therapeutics

New Agents for Head and Neck Cancer. Ezra Cohen, MD Associate Professor of Medicine University of Chicago Chicago, IL

Etiology and Pathogenesis

Generation of post-germinal centre myeloma plasma B cell.

CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION

ESC Congress August 2011 Paris France. VEGFs and the angiogenic paradox in diabetic patients

Endothelial Tube Formation Assay (In Vitro Angiogenesis)

JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T. preclinical development for cancer indications 6 and one, the vascular endothelial

Heart 3: Organogenesis, CHD, prenatal circulation

R J M E Romanian Journal of Morphology & Embryology

Inhibiting Vascular Endothelial Growth Factor Therapeutic Implications, Perspectives and Limitations

Vasculogenesis, angiogenesis and lymphangiogenesis: Signaling pathways

Cancer Metronomic Therapy Milan, February 26, 2016

Correlation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer

Use of Adipose-Derived Stem Cells in Regenerative Therapy. David Euhus, MD Professor of Surgery UT Southwestern Medical Center at Dallas

Stem Cell Therapy Concept. Pleuripotent Stromal Cells 8/8/2011. Use of Adipose-Derived Stem Cells in Regenerative Therapy

Lucitanib Program Overview. August 2018

This article is protected by copyright. All rights reserved.

Crosstalk between Adiponectin and IGF-IR in breast cancer. Prof. Young Jin Suh Department of Surgery The Catholic University of Korea

Deregulation of signal transduction and cell cycle in Cancer

Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma

H1L1, a humanized anti-fgf2 monoclonal antibody with potent anti-tumor activity in A549

COMPARATIVE VEGF RECEPTOR TYROSINE KINASE MODELING FOR THE DEVELOPMENT OF HIGHLY SPECIFIC INHIBITORS OF TUMOR ANGIOGENESIS

VEGFR-3 in Angiogenesis and Lymphangiogenesis

EGFR: fundamenteel en klinisch

3D-Tissue Microsystems for Tumor Microenvironments Designs for Basic and Translational Research

Targeting angiogenesis in cancer

Pathology MCQs. lipid. protein. glycogen. lipofuscin. water. Karyolysis. Cellular swelling. Involvement of a large number of cells

removed replaced inflammation scar tissue

Bevacizumab and ROP: Review of an RCT. M Chakraborty UHW

Citation: Chen, Wei (2015) Modelling of Tumour-induced Angiogenesis. Doctoral thesis, Northumbria University.

Vascular Endothelial Growth Factor in Human Colon Cancer: Biology and Therapeutic Implications

Paracrine Mechanisms in Adult Stem Cell Signaling and Therapy

Angiostasis and Angiogenesis Regulated by Angiopoietin1-Tie2 Receptor System

Imaging Cancer Treatment Complications in the Chest

I TESSUTI: Dott.ssa Liliana Belgioia Università degli Studi di Genova

Targeted and immunotherapy in RCC

2/1/2017. Agenda. David F. Williams, MD, MBA. History of Current Treatment. Current Treatment/Wet AMD Anti-VEGF Drugs. History of Current Treatment

Basic tumor nomenclature

WHY TARGETTING SIGNALLING PATHWAYS?

CANCER IMMUNOPATHOLOGY. Eryati Darwin Faculty of Medicine Andalas University

Downloaded from labdiagnosis.ir at 22: on Friday March 22nd angpt.

Current Status of Studies on Targeted Therapy for Renal Cell Carcinoma

IL-24 AND ITS ROLE IN WOUND HEALING

(PDGF), 9 ( -2 (FGF-2), SMO

OBJECTIVES. 1. List the major hallmarks of cancer. 2. Relate specific genes/proteins to individual hallmarks

Cell therapy: enhancing the therapeutic potential of cardiac progenitors for delivery post myocardial infarction. Rita Alonaizan

General Pathology VPM 152. Disorders of Cell Growth & Neoplasia. Lecture 4 Molecular basis of cancer

Lymphoid System: cells of the immune system. Answer Sheet

Cancer agents - Problem set #3

TITLE: Notch in Pathological Angiogenesis and Lymphangiogenesis

A Comparison of Endothelial Cell-Selective Adhesion Molecule and von Willebrand Factor Expression in Breast Cancer Growth and Metastasis

CANCER THERAPEUTICS: A NOVEL APPROACH

Overview of primary HHV-8 infection

Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle

THE BIOLOGY OF CANCER. Dr Jim Edwards Medical Oncologist Canterbury District Health Board

Bone Marrow Progenitor Cells and Vascular Endothelium: Studies on the In Vivo Differentiation Capacity and the Role of Bmx Tyrosine Kinase

The Role of Angiopoietin-2 in Signaling Through the Endothelial. Receptor Tyrosine Kinase Tie1

Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis

Review Article Angiogenesis in Spontaneous Tumors and Implications for Comparative Tumor Biology

Targeting Neuropilin-1 to Inhibit VEGF Signaling in Cancer: Comparison of Therapeutic Approaches

Transcription:

The Process of Angiogenesis & Inhibition of Angiogenesis and/or Lymphangiogenesis Nam Deuk Kim, Ph.D. Pusan National University

Contents Part 1. The process of angiogenesis Part 2. The role of angiopoietins in tumor angiogenesis Part 3. The role of angiogenesis and lymphangiogenesis in tumorigenesis Part 4. Angiogenesis inhibition by BIBF 1120, an investigational triple angiokinase inhibitor 2

Part 1: The Process of Angiogenesis Endothelial cell proliferation and the survival of new blood vessels

Angiogenesis is essential for tumor growth and metastasis Tumor growth requires an increased supply of oxygen and nutrients for endothelial cell proliferation and survival of new blood vessels 1-3 Angiogenesis supplies additional oxygen and nutrients to tumors 4 4 References: 1. Pugh CW, Ratcliffe PJ. Nat Med. 2003;9:677-684. 2. Bergers G, Benjamin LE. Nat Rev Cancer. 2003;3:401-410. 3. Acker T, Plate KH. Cell Tissue Res. 2003;314:145-155. 4. Hanahan D, Weinberg RA. Cell. 2000;100:57-70.

Hypoxia & necrosis of cells in poorly vascularized sections of tumor tissues Tumor parenchyma with capillaries (green) and hypoxic area (red) 5

Angiogenesis requires multiple growth factors and receptors Hypoxia is the primary stimulus for angiogenesis 1 Under hypoxic conditions, tumors produce and release multiple growth factors, including 2-6 : VEGFs bfgf PDGF TGF- -1 PlGF Angiopoietin-2 These growth factors stimulate receptors to initiate and regulate angiogenesis 7 6 References: 1. Acker T, Plate KH. Cell Tissue Res. 2003;314:145-155. 2. Pugh CW, Ratcliffe PJ. Nat Med. 2003;9:677-684. 3. Cao Y et al. J Clin Invest. 1996;98:2507-2511. 4. Calvani M et al. Blood. 2006;107:2705-2712. 5. Jiang Y et al. Acta Biochim Biophys Sin (Shanghai). 2007;39:73-80. 6. Lewis CE, Hughes R. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2. Breast Cancer Res. 2007;9:209. Available at: http://breast-cancer-research.com/content/9/3/209. Accessed March 17, 2008. 7. Ferrara N et al. Nat Med. 2003;9:669-676.

7 Angiogenic factors

Endogenous inhibitors of angiogenesis 8

9 Balancing the angiogenic switch

VEGF and PDGF pathways initiate and regulate angiogenesis Growth factors bind to the extracellular portion of receptors to stimulate activity 1 The intracellular portion of these receptors then initiates a chain of chemical reactions, resulting in cellular activity 1,2 Both VEGF and PDGF signaling pathways play key roles in angiogenesis 3,4 10 References: 1. Ullrich A, Schlessinger J. Cell. 1990;61:203-212. 2. Schlessinger J. Cell. 2000;103:211-225. 3. Ferrara N et al. Nat Med. 2003;9:669-676. 4. Yu J et al. J Biochem Mol Bio. 2003;36:49-59.

VEGF receptors play a central role in endothelial cell proliferation, migration, and survival The VEGFR family consists of 3 known receptors 1 : VEGFR-1 VEGFR-2 VEGFR-3 VEGFR-2 is the predominant receptor for endothelial cell proliferation and migration 1 VEGFR-2 provides a survival signal for new endothelial cells and vessel buds 1 11 Reference: 1. Ferrara N et al. Nat Med. 2003;9:669-676.

Angiogenesis involves multiple VEGF receptors VEGFR-1 and VEGFR-3 also play roles in angiogenesis and tumor metastasis 1-3 VEGFR-1 is expressed on multiple cell types 1,2,4,5 Endothelial cells (angiogenesis) Macrophages (metastasis) Tumor cells (survival) VEGFR-3 signaling induces the proliferation and growth of lymphatics, which may enhance metastasis 3 12 References: 1. Ferrara N et al. Nat Med. 2003;9:669-676. 2. Hiratsuka S et al. Cancer Cell. 2002;2:289-300. 3. Su JL et al. Br J Cancer. 2007;96:541-545. 4. Tsuchiya N et al. Tohoku J Exp Med. 2001;195:101-113. 5. Drescher D et al. World J Gastroenterol. 2007;13:3605-3609.

PDGFR- activity in pericytes plays a key role in established tumor vasculature PDGFR- signaling in pericytes is important for maturation, maintenance, and survival of established vessels 1,2 PDGFR- initiates pericyte proliferation and migration to newly formed endothelial cell buds 3 Pericytes contribute to the survival of new endothelial cell tubes through direct cell-to-cell contact and paracrine signaling 2,4 Blocking of pericyte migration to new blood vessels enhances endothelial cell apoptosis in response to VEGF pathway inhibition 5 13 References: 1. Bergers G et al. J Clin Invest. 2003;111:1287-1295. 2. Saharinen P, Alitalo K. J Clin Invest. 2003;111:1277-1280. 3. Benjamin LE et al. Development. 1998;125:1591-1598. 4. Pietras K et al. Cancer Cell. 2003;3:439-443. 5. Erber R et al. FASEB J. Available at: http://www.fasebj.org/cgi/reprint/03-0271fjev1. Accessed March 17, 2008.

In animal models, Simultaneous blockade of VEGFR and PDGFR- produced significant tumor regression Inhibition of VEGFR survival signaling inhibited tumor growth 1 Blocking PDGFR- and VEGFRs enhanced regression of tumor vasculature and tumors, compared with blocking VEGFRs alone 1,2 14 References: 1. Bergers G et al. J Clin Invest. 2003;111:1287-1295. 2. Potapova O et al. Mol Cancer Ther. 2006;5:1280-1289.

Current approaches to angiogenesis inhibition Signaling may be inhibited from outside or inside the cell 1 Monoclonal antibodies bind to growth factors or the extracellular portion of receptors 1 Receptor tyrosine kinase (RTK) inhibitors can bind to the intracellular portion of the receptor 1 As multiple growth factors may bind to a single receptor, intracellular blockade may be an effective anti-angiogenic approach 2 15 References: 1. Segota E, Bukowski RM. Cleve Clin J Med. 2004;71:551-560. 2. Ferrara N, Kerbel RS. Nature. 2005;438:967-974.

16 Heterotypic interactions as targets for therapeutic intervention

17 Angiogenesis inhibitors and their development & use in clinical trials

Angiogenesis: a complex process essential for tumor growth and metastasis Angiogenesis is essential for the growth and metastasis of most solid tumors 1,2 VEGFRs and PDGFR- initiate and regulate angiogenesis 3,4 VEGFRs play a central role in endothelial cell proliferation, migration, and survival 3 Intracellular blockade of VEGFR-1, -2, and -3 may be an effective approach to angiogenesis inhibition 5 PDGFR- signaling in pericytes is important for maturation, maintenance, and survival of established vessels 6,7 In animal models, blocking PDGFR- and VEGFRs enhanced regression of tumor vasculature and tumors compared with blocking VEGFRs alone 6,8 Current approaches to blocking growth factor regulation of angiogenesis include monoclonal antibody and RTK inhibitors 9 18 References: 1. Hicklin DJ, Ellis LM. J Clin Oncol. 2005;23:1011-1027. 2. Hanahan D, Weinberg RA. Cell. 2000;100:57-70. 3. Ferrara N et al. Nat Med. 2003;9:669-676. 4. Yu J et al. J Biochem Mol Biol. 2003;36:49-59. 5. Ferrara N, Kerbel RS. Nature. 2005;438:967-974. 6. Bergers G et al. J Clin Invest. 2003;111:1287-1295. 7. Saharinen P, Alitalo K. J Clin Invest. 2003;111:1277-1280. 8. Potapova O et al. Mol Cancer Ther. 2006;5:1280-1289. 9. Segota E, Bukowski RM. Cleve Clin J Med. 2004;71:551-560.

Part 2:

20

21

22

23

24

25

26

27

Part 3:

29

30

31

32

33

34

35

36

37 Part 4:

38

39

40

41

42

43

44